Current challenges in the treatment of high-risk non-metastatic RCC

“New regimens should now start to be explored, both…single-agent drugs as well as combination therapies,” says Pavlos Msaouel, MD, PhD.

In this video, Pavlos Msaouel, MD, PhD, discusses challenges that physicians face when treating patient with high-risk non-metastatic renal cell carcinoma, which were highlighted in his presentation, “The future of adjuvant therapy for high-risk non-metastatic RCC,” presented recently at the 2021 Society of Urologic Oncology Annual Meeting. Msaouel is an assistant professor in the department of genitourinary medical oncology of the division of cancer medicine at the University of Texas MD Anderson Cancer Center in Houston, Texas.